GlassScriptPhysician profile
Mark David Gelernt
NPI 1972556207
$12,918.41
in general payments reported to CMS, 2019-2025
42 companies · $996 in 2025
The $996 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,831 · 2020: $1,458 · 2021: $2,156 · 2022: $2,202 · 2023: $2,387 · 2024: $1,889 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,224 · Education: $48.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,223.66 |
| Education | $48.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,175.29 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,994.40 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,320.02 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Impulse Dynamics (USA) INC. | $1,157.29 | 2021-2025 | Optimizer, Optimizer |
| Pfizer INC. | $722.75 | 2019-2024 | |
| Abbott Laboratories | $607.83 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Perclose Prostyle, Navitor |
| Amgen INC. | $604.33 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $598.75 | 2019-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $421.58 | 2021-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $391.44 | 2021-2025 | |
| Amarin Pharma, INC. | $336.91 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $334.07 | 2020-2025 | Lifevest |
| Esperion Therapeutics, INC. | $302.82 | 2020-2024 | Nexletol |
| Novo Nordisk INC | $269.70 | 2021-2023 | Ozempic, Rybelsus |
| W. L. Gore & Associates, INC. | $245.06 | 2019-2022 |
Show all 38 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gelernt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.